Midostaurin US FDA Label
- Compound: N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide
- Description: Midostaurin is an organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine. It has a role as an EC 2.7.11.13 (protein kinase C) inhibitor and an antineoplastic agent. It is an indolocarbazole, an organic heterooctacyclic compound, a member of benzamides and a gamma-lactam. It is functionally related to a staurosporine.
- Brand Name:
- Code(s): PKC412;CGP 41251
- Approved:
- Kinase Class: RY
- Inhibitor Type: ?
- Literature (PubMed): 0
- Target(s): fms related receptor tyrosine kinase 3 , kinase insert domain receptor , Platelet derived growth factor receptor alpha , Platelet derived growth factor receptor beta , Protein kinase C alpha , Protein kinase C beta , Protein kinase C gamma
- Disease(s): acute myeloid leukemia , mantle cell lymphoma